Recent progress in the management of invasive fungal infections in hematopoietic stem cell transplant recipients

Future Microbiology

Volumn 3, Issue 5, 2008, Pages 493-496

  Maertens, Johan ^a   Bryan, Jenny ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIGEN; CASPOFUNGIN; GM ANTIGEN; POSACONAZOLE; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; BG TEST; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG COST; DRUG INDICATION; ENZYME IMMUNOASSAY; FEBRILE NEUTROPENIA; HALO SIGN; HUMAN; INCIDENCE; INVASIVE FUNGUS INFECTION; MORBIDITY; MORTALITY; MYCOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; RADIOLOGICAL PARAMETERS; SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNE DEFICIENCY; ITALY;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; ITALY; MYCOSES;

EID: 55449114040     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.3.5.493     Document Type: Conference Paper

References (16)

1. Pagano L, Caira M, Nosari A et al.: Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study: Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin. Infect. Dis. 45(9), 1161-1170 (2007).
2. Morgan J, Wannemuehler KA, Marr KA et al.: Incidence of invasive aspergillosis following haematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med. Mycol. 43(Suppl. 1), S49-S58 (2005).
3. Marr KA, Carter RA, Boeckh M, Martin P, Corey L: Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100(13), 4358-4366 (2002).
4. Guidelines from the First European Conference on Infections in Leukaemia: ECIL 1. Eur. J. Cancer 5(Suppl.), 1-59 (2007).
5. Walsh TJ, Anaissie EJ, Denning DW et al.: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Inect. Dis. 46, 327-360 (2008).
6. De Pauw B, Walsh TJ, Donnelly JP et al.: Revised definitions of invasive fungal disease and the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46, 1813-1821 (2008).
7. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am. J. Med. 72(1), 101-111 (1982).
8. No authors listed. Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am. J. Med. 86(6 Pt 1), 668-672 (1989).
9. Maertens J, Theunissen K, Verhoef G et al.: Galactomannan and computed tomography-based pre-emptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin. Infect. Dis. 41(9), 1242-1250 (2005).
10. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F: Empirical versus pre-emptive antifungal therapy in high-risk febrile neutropenic patients: a prospective randomized study. Blood 108, 2019 (2006) (ASH Annual Meeting Abstracts).
11. Marr KA. Laverdiere M, Gugel A, Leisenring W: Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin. Infect. Dis. 40(12), 1762-1769 (2005).
12. Greene RE, Schlamm HT, Oestmann JW et al.: Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin. Infect. Dis. 44(3), 373-379 (2007).
13. Ellis M, Al-Ramadi B, Finkelman M et al.: Assessment of the clinical utility of serial β-D-glucan concentrations in patients with persistent neutropenic fever. J. Med. Microbiol. 57(Pt 3), 287-295 (2008).
14. Cornely OA, Maertens J, Winston DJ et al.: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356(4), 348-359 (2007).
15. Ullmann AJ, Lipton JH, Vesole DH et al.: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356(4), 335-347 (2007).
16. Greiner R, Meier Y, O'Sullivan A, Imhof A: Cost effectiveness of posaconazole versus standard azole therapy for the prevention of invasive fungal infections in high-risk patients in Switzerland. Bone Marrow Transplant. 41(Suppl. 1), S339 (2008) (Abstract P1069).